Our top priority is the health and safety of our community. Visit our COVID-19 information page to see how we're responding to the public health emergency.

Photo of Hanna, living with carnitine-acylcarnitine translocase (CACT) deficiency

find hope in
a community.

Hear from others taking
DOJOLVI and their caregivers

Hear from others living with long chain fatty acid disorders (LC-FAOD ) who take DOJOLVI and their caregivers.

Photo of Hanna with her parents

Watch Hanna’s Story

Janelle and Mike share their daughter Hanna’s journey from being diagnosed with CACT to creating a treatment plan that works for their family as she transitions into daycare.

Watch Video


Watch Alexandra’s Story

Find out how Alexandra, living with LCHAD, navigates college independently with the support of her family, friends, and healthcare team.

Watch Video

Photo of Alexandra, living with LCHAD, a type of LC-FAOD

Photo of Daniel, living with carnitine palmitoyltransferase II (CPT II) definicency

Watch Daniel’s Story

Learn how Daniel, a college student living with CPT II, finds hope within his community and incorporates DOJOLVI into his daily routine.

Watch Video


Learn more about the resources and support that are available for you and your family

View Resources

Stay Informed

Connect with us to get the latest information on LC-FAOD and/or DOJOLVI.

*Required fields

By submitting this form, you agree to allow Ultragenyx and its agents to collect the information provided and to be contacted directly by an Ultragenyx representative. Your information will not be used for any other purpose than for a representative to respond to your information request or for us to send you other DOJOLVI updates if you have registered to receive them.

Ultragenyx will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Ultragenyx and its agents. Ultragenyx will only use your information in accordance with its Privacy Policy.

What is DOJOLVI?

DOJOLVI is a prescription medicine used to treat long-chain fatty acid oxidation disorders (LC-FAOD) in children and adults.

IMPORTANT SAFETY INFORMATION

Before taking DOJOLVI, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. It is not known if DOJOLVI will harm your unborn baby. Pregnancy Safety Study: There is a pregnancy safety study for women who take DOJOLVI during pregnancy. The purpose of this study is to collect information about your health and your baby's health. You can talk to your healthcare provider or contact 1-888-756-8657 to enroll in this study or get more information.
  • are breastfeeding or plan to breastfeed. It is not known if DOJOLVI passes into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take DOJOLVI.
  • are taking a pancreatic lipase inhibitor, such as orlistat, as it may affect how well DOJOLVI works.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of DOJOLVI?

  • Feeding tube problems. Feeding tubes may not work as well or stop working over time when taking DOJOLVI. Do not use DOJOLVI in feeding tubes made of polyvinyl chloride (PVC). Check the feeding tube to make sure it is working properly and not breaking down.
  • Intestinal absorption problems in patients with pancreatic insufficiency. If you have pancreatic insufficiency, consult with your healthcare provider as it may affect how well DOJOLVI works.
  • The most common side effects of DOJOLVI include:

These are not all the possible side effects of DOJOLVI. Call your healthcare provider for medical advice about side effects. You may report side effects to Ultragenyx Pharmaceutical Inc. at 1-888-756-8657 or FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information, for additional important safety information and instructions for use.

What is DOJOLVI?

DOJOLVI is a prescription medicine used to treat long-chain fatty acid oxidation disorders (LC-FAOD) in children and adults.

IMPORTANT SAFETY INFORMATION

Before taking DOJOLVI, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. It is not known if DOJOLVI will harm your unborn baby. Pregnancy Safety Study: There is a pregnancy safety study for women who take DOJOLVI during pregnancy. The purpose of this study is to collect information about your health and your baby's health. You can talk to your healthcare provider or contact 1-888-756-8657 to enroll in this study or get more information.
  • are breastfeeding or plan to breastfeed. It is not known if DOJOLVI passes into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take DOJOLVI.
  • are taking a pancreatic lipase inhibitor, such as orlistat, as it may affect how well DOJOLVI works.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of DOJOLVI?

  • Feeding tube problems. Feeding tubes may not work as well or stop working over time when taking DOJOLVI. Do not use DOJOLVI in feeding tubes made of polyvinyl chloride (PVC). Check the feeding tube to make sure it is working properly and not breaking down.
  • Intestinal absorption problems in patients with pancreatic insufficiency. If you have pancreatic insufficiency, consult with your healthcare provider as it may affect how well DOJOLVI works.
  • The most common side effects of DOJOLVI include:

These are not all the possible side effects of DOJOLVI. Call your healthcare provider for medical advice about side effects. You may report side effects to Ultragenyx Pharmaceutical Inc. at 1-888-756-8657 or FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information, for additional important safety information and instructions for use.